Document Detail


Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.
MedLine Citation:
PMID:  21653684     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Peloruside A and laulimalide are potent microtubule-stabilizing natural products with a mechanism of action similar to that of paclitaxel. However, the binding site of peloruside A and laulimalide on tubulin remains poorly understood. Drug resistance in anticancer treatment is a serious problem. We developed peloruside A- and laulimalide-resistant cell lines by selecting 1A9 human ovarian carcinoma cells that were able to grow in the presence of one of these agents. The 1A9-laulimalide resistant cells (L4) were 39-fold resistant to the selecting agent and 39-fold cross-resistant to peloruside A, whereas the 1A9-peloruside A resistant cells (R1) were 6-fold resistant to the selecting agent while they remained sensitive to laulimalide. Neither cell line showed resistance to paclitaxel or other drugs that bind to the taxoid site on β-tubulin nor was there resistance to microtubule-destabilizing drugs. The resistant cells exhibited impaired peloruside A/laulimalide-induced tubulin polymerization and impaired mitotic arrest. Tubulin mutations were found in the βI-tubulin isotype, R306H or R306C for L4 and A296T for R1 cells. This is the first cell-based evidence to support a β-tubulin-binding site for peloruside A and laulimalide. To determine whether the different resistance phenotypes of the cells were attributable to any other tubulin alterations, the β-tubulin isotype composition of the cells was examined. Increased expression of βII- and βIII-tubulin was observed in L4 cells only. These results provide insight into how alterations in tubulin lead to unique resistance profiles for two drugs, peloruside A and laulimalide, that have a similar mode of action.
Authors:
Arun Kanakkanthara; Anja Wilmes; Aurora O'Brate; Daniel Escuin; Ariane Chan; Ada Gjyrezi; Janet Crawford; Pisana Rawson; Bronwyn Kivell; Peter T Northcote; Ernest Hamel; Paraskevi Giannakakou; John H Miller
Related Documents :
21865464 - Mmp2-9 cleavage of dystroglycan alters the size and molecular composition of schwann ce...
21718714 - Toxicity and differential protein analysis following destruxin a treatment of spodopter...
990964 - Paraventricular nucleus: changes in the medial and lateral cell groups during dehydrati...
21737914 - Sublethal doses of surfactants induce premature senescence in normal human skin cells.
21537844 - Autophagy and cell death signaling following dietary sulforaphane act independently of ...
8203534 - Maintenance of cellular acidification in cyanide-treated hepatocytes results from inhib...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-06-08
Journal Detail:
Title:  Molecular cancer therapeutics     Volume:  10     ISSN:  1538-8514     ISO Abbreviation:  Mol. Cancer Ther.     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-08-10     Completed Date:  2011-12-19     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  101132535     Medline TA:  Mol Cancer Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1419-29     Citation Subset:  IM    
Copyright Information:
©2011 AACR
Affiliation:
School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / metabolism,  pharmacology*
Bicyclo Compounds, Heterocyclic / metabolism,  pharmacology*
Binding Sites
Cell Line, Tumor
Drug Resistance, Neoplasm / genetics
Female
Humans
Lactones / metabolism,  pharmacology*
Macrolides / metabolism,  pharmacology*
Mutation / genetics*
Ovarian Neoplasms / genetics*,  metabolism,  pathology
Protein Binding
Protein Multimerization / drug effects
Tubulin / genetics*,  metabolism
Grant Support
ID/Acronym/Agency:
CA100202/CA/NCI NIH HHS; R01 CA114335/CA/NCI NIH HHS; Z99 CA999999/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Bicyclo Compounds, Heterocyclic; 0/Lactones; 0/Macrolides; 0/Tubulin; 0/laulimalide; 0/peloruside A
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell aden...
Next Document:  Enhanced anti-tumor effects by chemical modified iGb3 analogues via increasing stability of the CD1d...